Literature DB >> 8326743

The role of integrins in granulocyte dysfunction in myelodysplastic syndrome.

G Ricevuti1, A Mazzone, D Pasotti, G Fossati, I Mazzucchelli, A Notario.   

Abstract

The aim of the present study was to evaluate the function of granulocytes in 20 patients affected by myelodysplastic syndrome (MDS) and correlate this with the expression of surface membrane integrins. The granulocytes showed a deficit in chemotaxis (34 +/- 12 vs 84 +/- 10, p < 0.01) in superoxide release (12 +/- 7 vs 30 +/- 10, p < 0.01) and in aggregation 12 +/- 6 vs 36 +/- 9, p < 0.01 using fMLP as stimulus. We also demonstrated with cytofluorimetric and alkaline phosphatase immunoenzymatic analysis (APAAP), decreased expression of CD11b/CD18 receptor detected by OKM1 (p < 0.001) and CD18 detected by MoAb IOT-18 (p < 0.001). PMNs CD11b/CD18 up-regulation and APAAP image analysis studies showed a lower level of expression of CD11b/CD18 in granulocytes from MDS patients compared to controls (p < 0.001). We concluded that granulocyte dysfunction in MDS may be correlated with modification of leukocyte integrins.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8326743     DOI: 10.1016/0145-2126(93)90092-y

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

Review 1.  Infections in myelodysplastic syndromes.

Authors:  Andréa Toma; Pierre Fenaux; François Dreyfus; Catherine Cordonnier
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

2.  Neutrophil adhesion molecules in HIV disease.

Authors:  D A Moore; D Henderson; B G Gazzard
Journal:  Clin Exp Immunol       Date:  1998-10       Impact factor: 4.330

3.  Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study.

Authors:  Kathleen M Wesa; Susanna Cunningham-Rundles; Virginia M Klimek; Emily Vertosick; Marci I Coleton; K Simon Yeung; Hong Lin; Stephen Nimer; Barrie R Cassileth
Journal:  Cancer Immunol Immunother       Date:  2014-10-29       Impact factor: 6.968

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.